Cocaine use is on the rise across New Zealand workplaces. That’s a key finding of the latest Imperans Report, a quarterly analysis of drug use in the workplace prepared by The Drug Detection Agency (TDDA), New Zealand’s largest workplace drug testing provider.
The Imperans report empowers New Zealand employers to engage in proactive workplace risk management, it provides them with an analysis of drug and alcohol usage trends, combining results from across the country.
Growing cocaine use is not the only workplace concern. Among all positive results across New Zealand, compared with year-on-year (YoY) substance detections are as follows.
Cocaine: 2.8% of positive tests, up 68.5% YoY
ATS (including methamphetamine): 32.7% of positive tests, up 5.2% YoY
Cannabis: 64.4% of positive tests, up 1.7% YoY
If there’s a silver lining, it’s that opioid use (including oxycodone) is down. Opioids were present in 18.2% of positive tests, in Q2, down 14.0% YoY.
This quarter, 2.8% of all screens conducted by TDDA indicated the presence of drugs, showing a slight downward trend compared with 3.0% in Q1. Of positive test rates, there is a backdrop of cocaine and ATS rebounding strongly against the same quarter a year ago.
Cocaine accounted for 2.8% of positive tests in Q2 2026, up 68.5% YoY, and setting aside the seasonal Q4 peak, its highest level in a year.
“TDDA data is showing that cocaine retreated from Q4 levels, which peaked over Christmas and New Year, but is roaring back in Q2. It is becoming increasingly likely that cocaine, buoyed by cartels and other South Pacific drug trade activity, is something employers even in white collar industries need to worry about. The substance is becoming highly available due to supply networks – rather than just a one-off spike,” says Glenn Dobson, chief executive of TDDA.
ATS, including methamphetamine, accounted for 32.7% of positive tests, up 5.2% YoY, after easing since Q3 2025. Businesses in the South Island should take note, as the region is seeing the largest spike in positive rates.
Opioids accounted for 18.2% of positive tests, down 14.0% YoY, while cannabis accounted for 64.4% of positive tests, up 1.7% YoY. Detection rates for both remain stubbornly high.
“Cocaine and ATS interfere with the way the brain judges risk, producing misplaced confidence and slower decisions at exactly the wrong moment. On safety-critical sites, where a small margin or a split second can be the difference, that combination can turn deadly fast. When judgement slips on a construction site or behind the wheel of a truck, the consequences reach past the workers and colleagues, and into families waiting at home.”